Natco Pharma to set up subsidiary in Indonesia with investment of $3 mn

Natco will initially invest USD 1 million for a stake of 51 per cent as capital contribution and balance will be invested as and when the funds are required by the subsidiary, it added

pharmacy, drugs, medicine, pharma companies, pharmaceuticals, vaccine, coronavirus, covid, testing
Representative Image
Press Trust of India New Delhi
1 min read Last Updated : Apr 20 2023 | 2:25 PM IST

Natco Pharma Ltd on Thursday said its board has approved setting up of a subsidiary in Indonesia with an investment of up to USD 3 million (nearly Rs 25 crore) for selling pharmaceutical products in that country.

The new subsidiary -- PT. NATCO Lotus Farma -- will be a joint venture with Natco holding 51 per cent and the balance stake 49 per cent by PT. Mitra Medis Exim (MME), a part of Mitra Jaya Group, which is a 40 year old multi-diversified group, as the co-promoter, the company said in a regulatory filing.

The company's board approved the proposal at its meeting held on Thursday.

Natco will initially invest USD 1 million for a stake of 51 per cent as capital contribution and balance will be invested as and when the funds are required by the subsidiary, it added.

PT. NATCO Lotus Farma will be engaged in selling pharmaceutical products in Indonesia, it added.

MME is in the business of distribution for active pharmaceutical ingredients and excipients for end-users in Indonesia.

On the rationale behind the step, Natco said,"(The) objective is to enter new geographies for growth and increased profitability.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :NatcoNatco PharmaIndonesiaIndian pharma companies

First Published: Apr 20 2023 | 1:10 PM IST

Next Story